Cerecor has acquired exclusive, worldwide rights from Eli Lilly to develop and commercialize LY2456302 (which will be designated as CERC-501), a Phase 2-ready, potent and selective kappa opioid receptor (KOR) antagonist.
KORs are believed to play a key role in modulating stress, mood and addictive disorders.
Research also suggests that selective KOR antagonists can block both the physical and emotional symptoms of nicotine withdrawal.
|Searching for more deal information? Current Partnering offers the following options:
Under the terms of the agreement, Cerecor will immediately assume full development and commercialization responsibilities of CERC-501.
License consideration includes undisclosed milestone payments and royalties.
Cerecor anticipates completing the technology transfer activities by mid-2015 and initiating clinical trials in the second-half of the year.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies